Metabolic Syndrome and Fingertip Endothelial Dysfunction
Achievement of Dietetic and Exercise Therapy Evaluated by Self-assessment Score Significantly Improved Endothelial Dysfunction in Patients With Metabolic Syndrome
1 other identifier
interventional
70
1 country
1
Brief Summary
Life-style intervention with dietetic and exercise therapy is an important fundamental approach to patients with metabolic syndrome (MetSyd) which may cause endothelial dysfunction leading to cardiovascular events. We investigated whether the life-style modification by dietetic and exercise instruction could improve endothelial dysfunction assessed by a new non-invasive and automatic device; digital reactive hyperemia peripheral arterial tonometry (RH-PAT).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Aug 2006
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2006
CompletedFirst Submitted
Initial submission to the registry
November 2, 2009
CompletedFirst Posted
Study publicly available on registry
November 3, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2011
CompletedSeptember 26, 2013
September 1, 2013
5.3 years
November 2, 2009
September 25, 2013
Conditions
Outcome Measures
Primary Outcomes (1)
Endothelial function assessed by RH-PAT
About 1 year later
Secondary Outcomes (1)
Metabolic status including waist circumference
About 1 year later
Study Arms (1)
Lifestyle instruction
OTHERInterventions
Eligibility Criteria
You may qualify if:
- Under 70 years old and preserved left ventricular systolic function (left ventricular ejection fraction ≥ 50%)
You may not qualify if:
- Severe valvular heart disease
- Atrial septal defect
- Myocarditis
- Cardiomyopathy
- Active inflammatory diseases
- Pulmonary hypertension
- Chronic kidney disease on hemodialysis
- Advanced hepatic disease
- Leukemia
- Schizophrenia; AND
- Cerebrovascular disease and residual hemiplegia.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Kumamoto University Hospital
Kumamoto, Kumamoto, 860-8556, Japan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD, PhD
Study Record Dates
First Submitted
November 2, 2009
First Posted
November 3, 2009
Study Start
August 1, 2006
Primary Completion
December 1, 2011
Study Completion
December 1, 2011
Last Updated
September 26, 2013
Record last verified: 2013-09